| Business Summary | | Bristol-Myers
Squibb
Company
is
a
major
producer
and
distributor
of
medicines.
The
Company's
products
include
PRAVACHOL,
GLUCOPHAGE,
TAXOL,
PLAVIX,
BUSPAR,
PARAPLATIN,
ZERIT,
MONOPRIL,
CEFZIL,
AVAPRO,
SERZONE,
CAPOTEN/CAPOZIDE,
EXCEDRIN,
VIDEX,
infant
formulas,
ostomy
products,
and
wound
care
products.
On
September
28,
2000,
the
Company
announced
the
planned
divestiture
of
its
Clairol
and
Zimmer
businesses.
The
Company
announced
on
February
22,
2001
its
intention
to
separate
the
Zimmer
business
in
a
tax-free
spin-off
to
shareholders.
The
transaction
was
completed
in
August,
2001. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Bristol-Myers
Squibb
Company,
through
its
divisions
and
subsidiaries,
is
a
producer
and
distributor
of
consumer
medicines,
pharmaceuticals,
nutritionals,
medical
devices
and
beauty
care
products.
For
the
six
months
ended
6/30/01,
net
sales
rose
6%
to
$9.40
billion.
Net
income
from
continuing
operations
rose
10%
to
$2.35
billion.
Results
reflect
increases
in
both
volume
and
selling
prices
of
pharmaceutical
products,
and
reduced
expenditures
for
advertising
and
promotion. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Charles Heimbold, Jr., 67 Chairman | $3.5M | Peter Dolan, 45 Pres,
CEO, Director | 6.7M | Frederick Schiff, 53 CFO,
Sr. VP | -- | Peter Ringrose, Ph.D., 54 CSO
and Pres, Bristol-Myers Squibb Pharmacuetical Research Institute | -- | John McGoldrick, 60 Exec.
VP and Gen. Counsel and Pres, Medical Devices Group | 1.2M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|